Table 2 Principal characteristics of the 15 studies included in the meta-analysis
Study | Publication year | Number of patients | Study design | PET/CT timing | Type of treatment | End pointsa | Methodology score (%) |
|---|---|---|---|---|---|---|---|
de Geus-Oei L F et al. | 2006 | 152 | Retrospective | Pretreatment | Resection or Chemotherapy | OS | 83.33Â % |
Small RM et al. [21] | 2009 | 54 | retrospective | Pretreatment and posttreatment | Chemotherapy | OS EFS(PFS) | 50.00Â % |
Hendlisz A et al. | 2011 | 41 | Prospective | Pretreatment and posttreatment | Chemotherapy | OS EFS(PFS) | 70.83Â % |
Muralidharan V et al. | 2012 | 30 | retrospective | Pretreatment | Resection | OS EFS(RFS) | 75.00Â % |
De Bruyne S et al. [22] | 2012 | 19 | Retrospective | Pretreatment and posttreatment | Chemotherapy and bevacizumab | EFS(PFS) | 75.00Â % |
Lastoria S et al. | 2013 | 33 | Retrospective | Pretreatment and posttreatment | Chemotherapy and Bevacizumab | EFS(PFS) OS | 66.67Â % |
Mertens J et al. [23] | 2013 | 18 | Prospective | Pretreatment and posttreatment | Chemotherapy and Bevacizumab | OS | 75.00Â % |
Zerizer I et al. | 2013 | 25 | Retrospective | Pretreatment and posttreatment | 90Y radioembolization | EFS(PFS) | 70.83Â % |
Fendler W P et al. | 2013 | 80 | Retrospective | Pretreatment and posttreatment | 90Y radioembolization | OS | 62.50Â % |
Jones C et al. | 2014 | 79 | retrospective | Pretreatment | Resection | OS | 54.17Â % |
Lee HS et al. [24] | 2014 | 120 | retrospectively | Pretreatment | Resection | OS EFS(RFS) | 83.33Â % |
Lau LF et al. | 2014 | 37 | retrospective | Pretreatment and posttreatment | Chemotherapy | OS EFS(RFS) | 58.33Â % |
Riedl CC et al. [25] | 2007 | 90 | retrospective | Pretreatment | Resection | OS | 54.17Â % |
Correa-Gallego C et al. | 2015 | 38 | Prospective | Pretreatment and posttreatment | Chemotherapy and bevacizumab | OS EFS(PFS) | 83.33Â % |
Sabet A et al. | 2015 | 51 | retrospective | Pretreatment and posttreatment | 90Y radioembolization | OS | 70.83Â % |